Umme Habiba Faisal

Umme Habiba Faisal

Auto-generated profile, based on publicly available information

Umme Habiba Faisal

Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2024 in Journal of Global Health
Verified
Journal Article
Open access
TATanya Amal
Tanya Amal
Akshat BangaAkshat Banga
Akshat Banga
GBGaurang Bhatt
Gaurang Bhatt
UFUmme Habiba Faisal
Umme Habiba Faisal
AKAisha Khalid
Aisha Khalid
GPGlobal Remote Research Scholars Program
Global Remote Research Scholars Program
Violence against health care workers (HCWs) has emerged as a significant global challenge, representing a major concern for practitioners, society, organisations, and patients [1]. It can present in many forms, ranging from verbal aggressions to serious physical assaults [2], as well as cyberbullying through using various social media platforms [3]. There is also internal violence […]

6 January 2026 in Neurosurgical Review
Verified
Journal Article
Open access
PDF file
NDNoah Drewes
Noah Drewes
JNJeffrey Z. Nie
Jeffrey Z. Nie
RCRafal Chojak
Rafal Chojak
KNKhizar Rehan Nandoliya
Khizar Rehan Nandoliya
RJRishi Jain
Rishi Jain
LALeslie Acakpo-Satchivi
Leslie Acakpo-Satchivi
Undifferentiated pleomorphic sarcoma (UPS) is a rare and aggressive soft tissue tumor of unknown histogenesis. UPS most often arises in the extremities or trunk, where wide surgical excision is feasible. Rarely, UPS involves the intracranial space, where critical structures may inhibit complete resection. Given its rarity and historical misclassification as malignant fibrous histiocytoma (MFH), knowledge of intracranial UPS is limited, and there are no clear treatment guidelines. We systematically reviewed all available cases of intracranial UPS to consolidate existing literature and assess prognosis and management considerations. A systematic review was conducted according to PRISMA guidelines. PubMed and Embase were searched for reports of intracranial UPS or storiform-pleomorphic MFH. Eligible studies included at least one histologically confirmed case treated with surgery, chemotherapy, or radiotherapy and reported outcomes. Data on demographics, tumor location, treatment, follow-up, and survival were extracted. Event-free survival (EFS) and overall survival (OS) were analyzed by treatment modality, age, sex, and tumor location using Kaplan-Meier and log-rank tests. From 801 records, 40 studies with 48 patients were included. The median age was 45 years, and 50% were female. 15% had prior radiotherapy. Most tumors were extra-axial (45%) and nearly all patients underwent surgery, with 82.1% achieving gross total resection. Median EFS and OS were 18 and 24 months, respectively. No survival differences were seen by treatment modality, age, or sex. Overall survival was longer for extra-axial tumors compared to intra-axial or skull base tumors ( p = 0.016). Intracranial UPS is a rare and aggressive tumor, with worse prognosis compared to those that are extracranial. Among factors that we evaluated, extra-axial location was the strongest positive prognostic factor. Surgical resection with adjuvant chemoradiation showed the longest median survival. Ongoing case reports are required to refine management guidelines and improve patient outcomes.

24 December 2025
Verified
Dataset
Closed access
PDF file
IOIan Edward Olson
Ian Edward Olson
RCRafal Chojak
Rafal Chojak
UFUmme H. Faisal
Umme H. Faisal
JTJillyn Turunen
Jillyn Turunen
ILIrene Lazanyi
Irene Lazanyi
Atique AhmedAtique Ahmed
Atique Ahmed
Diseases of the central nervous system (CNS) manifest through a complex, dynamic network of intercellular communication. Glioblastoma (GBM), the most common and aggressive primary brain tumor, is emblematic of this complexity, with its rapid progression and dismal prognosis measured in months rather than years. GBM's biology is driven by intricate signaling molecule exchanges between neoplastic and stromal cells, underpinning aggressive disease progression. Here, we describe a detailed cerebral open-flow microperfusion (cOFM) protocol in GBM mouse models, enabling real-time longitudinal monitoring of tumor microenvironment dynamics within the interstitial fluid (ISF). Our approach describes the implantation of durable guide cannula head-mounts, their use for intracerebral glioma engraftment directly through the guide, and the collection of high-fidelity cOFM samples for metabolomic and proteomic LC-MS analyses. Crucially, cOFM overcomes the molecular size limitations of traditional microdialysis. Beyond GBM, cOFM methodology promises transformative insights into a spectrum of CNS disorders, including neurodegenerative, epileptic, and neuropsychiatric conditions, through its capacity to provide etiological and treatment-responsive biomarkers within their respective animal models.

23 December 2025 in Journal of Visualized Experiments
Verified
Journal Article
Closed access
PDF file
IOIan Edward Olson
Ian Edward Olson
RCRafal Chojak
Rafal Chojak
UFUmme H. Faisal
Umme H. Faisal
JTJillyn Turunen
Jillyn Turunen
ILIrene Lazanyi
Irene Lazanyi
Atique AhmedAtique Ahmed
Atique Ahmed
Diseases of the central nervous system (CNS) manifest through a complex, dynamic network of intercellular communication. Glioblastoma (GBM), the most common and aggressive primary brain tumor, is emblematic of this complexity, with its rapid progression and dismal prognosis measured in months rather than years. GBM's biology is driven by intricate signaling molecule exchanges between neoplastic and stromal cells, underpinning aggressive disease progression. Here, we describe a detailed cerebral open-flow microperfusion (cOFM) protocol in GBM mouse models, enabling real-time longitudinal monitoring of tumor microenvironment dynamics within the interstitial fluid (ISF). Our approach describes the implantation of durable guide cannula head-mounts, their use for intracerebral glioma engraftment directly through the guide, and the collection of high-fidelity cOFM samples for metabolomic and proteomic LC-MS analyses. Crucially, cOFM overcomes the molecular size limitations of traditional microdialysis. Beyond GBM, cOFM methodology promises transformative insights into a spectrum of CNS disorders, including neurodegenerative, epileptic, and neuropsychiatric conditions, through its capacity to provide etiological and treatment-responsive biomarkers within their respective animal models.

22 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
RCRafal Chojak
Rafal Chojak
UFUmme H. Faisal
Umme H. Faisal
PKPriya U. Kumthekar
Priya U. Kumthekar
NDNoah Drewes
Noah Drewes
LKLara Koutah
Lara Koutah
Atique AhmedAtique Ahmed
Atique Ahmed
Background: Glioblastoma (GBM) adapts to therapy through coordinated malignant-cell and microenvironmental responses, but the mechanisms linking treatment-associated inflammation to tumor-cell phenotypic plasticity remain poorly defined. Here, we investigated whether preoperative temozolomide exposure is associated with inflammatory-repair remodeling and a ROCK-linked therapeutic vulnerability in recurrent GBM using a window-of-opportunity clinical trial cohort. Methods: We integrated patient-resolved single-cell transcriptomics, spatial RNA profiling and multiplex protein imaging with experimental perturbations and orthotopic glioblastoma models. In the presurgical window-of-opportunity subgroup of NCT05236036 , four patients with recurrent glioblastoma received additional preoperative temozolomide (TMZ; 150 mg/m2/day for 5 days) before resection and were compared with three recurrent comparators who did not receive additional preoperative TMZ. Results: Across seven tumors, malignant-cell inflammatory activity covaried with integrin-binding and wound-healing programs (median partial ρ = 0.45 and 0.42, respectively). Tumors exposed to preoperative TMZ showed enrichment of inflammatory, chemokine, adhesion and wound-healing programs (GSEA q < 0.05), with the direction of enrichment preserved in all leave-one-patient-out analyses. In two tumors exposed to preoperative TMZ, CXCL12 localized to vascular territories, whereas chemokine and wound-repair programs increased near injury-reference regions. Across seven specimens analyzed by multiplex protein imaging, MYL9 abundance correlated with local CXCL12 (ρ = 0.61), phosphorylated MYPT1 (ρ = 0.48) and nuclear phosphorylated STAT3 (ρ = 0.45), with positive associations in every specimen. Experimentally, TMZ increased CXCL8 and reactive-state markers and enhanced subsequent scratch closure, while CXCL8 and CXCL12 increased MLC2 phosphorylation. Fasudil attenuated TNF-NF-κB, inflammatory-response and IFN-γ-response programs in TMZ-treated cells and reduced scratch closure and p-MLC2 in complementary assays. Across three orthotopic models, fasudil plus TMZ prolonged survival versus TMZ alone (model-stratified HR, 0.21; 95% CI, 0.07-0.61; P = 0.001). Conclusions: These findings link treatment-associated inflammatory-repair programs with cytoskeletal remodeling and support further translational evaluation of fasudil plus TMZ in glioblastoma.